Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study.
The levonorgestrel-releasing intrauterine system may represent an effective treatment option in >85% of endometrial hyperplasia cases, but histologic regression during and/or at the end of treatment does not assure stable recovery. We recommend periodic endometrial samplings for at least the first 2 years of follow-up and long-term clinical surveillance thereafter.
Scarselli
Gianfranco
G
Department of Gynecology, Perinatology, and Human Reproduction, University of Florence, Florence, Italy.
Bargelli
Gianni
G
Taddei
Gian Luigi
GL
Marchionni
Mauro
M
Peruzzi
Elena
E
Pieralli
Annalisa
A
Mattei
Alberto
A
Buccoliero
Anna Maria
AM
Fambrini
Massimiliano
M
D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D007434:Intrauterine Devices; D016912:Levonorgestrel / Q000008:administration & dosage*; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome
D003271:Contraceptive Agents, Female; D016912:Levonorgestrel